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Abstract 
 
 
Regulation of SCD1 expression 
by the Polysiphonia morrowii extract 
 
 
Na Rae Lee 
 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
 
(Directed by Professor Sahng Wook Park) 
 
 
SCD1 (Stearoyl-Coenzyme A desaturase 1) is the rate-limiting 
enzyme that catalyzes the synthesis of monounsaturated fatty acids 
from saturated fatty acids. The unsaturated fatty acids produced by 
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SCD1 are essential for the biosynthesis of triglycerides. Increased 
SCD1 expression and activity has been implicated in many disease 
conditions as in obesity, insulin resistance, cardiovascular diseases, and 
cancer. Recently, it has been suggest that inhibition of SCD1 is a 
modality to control lipogenesis and body weight, and to treat obesity 
and hyperglyceridemia.  
In this study, the effect of the Polysiphonia morrowii extract on the 
plasma concentration of triglyceride was studied with regard to 
regulation of the SCD1 expression. Mice fed with a chow diet 
supplemented with the P. morrowii extract showed the lower plasma 
triglyceride level than that in control mice. Microarray analysis of 
mRNAs in livers revealed that the expression of Scd1 was down-
regulated by the extract significantly. The reduced expression of Scd1 
was confirmed by quantitative real-time PCR and Western blot analysis 
in livers of mice. The treatment HepG2 cells with the P. morrowii 
extract reduced both SCD1 mRNA and protein in a-dose dependent 
manner. In addition, the extract reduced the expression of the Scd1 
mRNA and protein in 3T3-L1 cells during the process of differentiation 
from pre-adipocyte to adipocyte. The P. morrowii extract was able to 
repress the transcription of SCD1 regardless of mutations of conserved 
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regulatory elements, such as LXRE, C/EBP, and SRE in the SCD1 
promoter. 
In conclusion, the extract P. morrowii down-regulates the 
expression of SCD1 at the transcriptional level mediated by 
unidentified transcriptional factors, and it is suggested that the P. 
morrowii extract has the therapeutic potential for treatment of 
hyperglyceridemia by down-regulating the expression of SCD1. 
 
 
 
 
 
 
 
 
 
 
Key words: hyperglyceridemia, stearoyl-CoA desaturase, 
unsaturated fatty acid, cardiovascular disease, Polysiphonia morrowii, 
triglyceride, transcription  
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I. INTRODUCTION 
The increased triacylglycerol (TG) concentration in plasma is one of 
the important parameters related to the increased incidence of 
cardiovascular disease (CVD)1,2. Plasma TG exists as associated with 
other lipids in lipoproteins such as very low-density lipoprotein or low-
density lipoprotein rather than as TG itself3. As the ratio of low density 
lipoprotein-cholesterol or total cholesterol versus high density 
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lipoprotein-cholesterol is considered to be the important predictor of 
CVD, the increased TG level with insulin resistance is a key metabolic 
abnormality in metabolic syndrome and future development of 
diabetes4,5. In general, it is strongly suggested that pharmacological 
reduction of the plasma TG level has beneficial health effects 
particularly in patient with obesity and diabetes6. The current 
therapeutic interventions for reduction of the plasma TG level in 
patients with obesity and type 2 diabetes are statins, intestinal 
cholesterol absorption inhibitors, fibrates, niacin, n-3 fatty acids, and 
glucagon-like peptide-1, with additional dietary and lifestyle 
modifications7. 
Currently, strategies to reduce the plasma TG level by inhibition of 
specific enzymes involved in de novo TG biosynthesis are under 
investigation very intensively8,9. For example, inhibitors of acyl-
CoA:diacylglycerol acyltransferase 1 (DGAT1) are reported to improve 
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insulin sensitivity and hepatic steatosis9. Recently, stearoyl-CoA 
desaturase (SCD; EC 1.44.99.5) has also been elucidated as a potential 
target for the treatment of obesity and associated disorders10. 
SCD is an iron-containing enzyme catalyzing a rate limiting step in 
the synthesis of monounsaturated fatty acids from saturated fatty acids11. 
SCD introduces a double bond between carbon atoms 9 and 10 in 
palmitoyl- or stearoyl-CoA to produce palmitoleoyl- or oleoyl-CoA, 
respectively. This generation of monounsaturated fatty acids by SCD is 
important in biosynthesis of TG, membrane phospholipids and 
cholesterol ester12,13, and in regulation of membrane fluidity14, cellular 
differentiation, and apoptosis15,16. Four Scd isoforms, Scd1 through 
Scd4, have been identified in mouse17, while two SCD isoforms (SCD1 
and SCD5) have been identified in human18-20. SCD1 is a constituent of 
the lipid metabolism predominantly expressed in adipose tissues and 
liver21, while SCD5 is a unique isoform expressed in brain and 
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pancreas19,22. The expression of SCD1 is regulated by several dietary 
and hormonal factors, such as high-carbohydrate diets23-25, insulin and 
fructose26, glucose27, polyunsaturated fatty acids25,28, cholesterol28-30, 
retinoic acid30,31, and fibrates30,32,33. The mechanism of all these 
regulations involves the activation of sterol regulatory element-binding 
protein-1c (SREBP-1c) which is a key transcription factor for the 
expression of several lipogenic genes29,33-35. 
The significance of SCD1 as a therapeutic target has been derived 
from the fact that the expression and activity of SCD1 are increased in 
several disorders, such as cancer36,37, cardiovascular disease38, 
obesity10,13,39,40, steatosis41, insulin resistance42, metabolic syndrome43, 
and diabetes42. In particular, studies in Scd1 knockout mice elucidated 
how valuable the inhibition of SCD1 is in the control of obesity and 
related metabolic disorders. In Scd1-/- mice, fatty acid oxidation in 
mitochondria is increased in liver, skeletal muscle, and brown adipose 
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tissue, while lipogenesis is not induced by a diet high in saturated fat 
diet44-46. It has also been reported in Scd1-/- mice that signaling of 
insulin and AMP-activated protein kinase are enhanced in skeletal 
muscle and brown adipose tissue45,47 while the lipid accumulation and 
adiposity are decreased40,41. The hepatic TG and cholesterol ester 
synthesis are greatly reduced in Scd1-/- mice, and the concentration of 
plasma TG decreases by 67% in these mice48. In addition to the loss of 
functional SCD1 in genetic models, pharmacological inhibition of 
SCD1 using SCD1-specific antisense oligonucleotide inhibitors reduce 
the synthesis and secretion of fatty acid, while they increase fatty acid 
oxidation in primary mouse hepatocytes, and prevent diet-induced 
obesity in mice49. 
In summary, the inhibition of SCD1 expression and activity is 
suggested to be a potential therapeutic target in the prevention of 
metabolic diseases. In this study, the extract of Polysiphonia morrowii 
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was evaluated in vivo and in vitro as a potential candidate of SCD1 
inhibitors.  
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II. MATERIALS AND METHODS 
1. General methods and supplies 
Delipidated serum (DLPS) was prepared from fetal bovine serum 
(Invitrogen Brand, Life Technologies, Carlsbad, CA, USA) as described 
by Hannah et al.50. Protein concentrations were determined using a 
BCA kit (Pierce, Rockford, IL, USA). Cell culture medium and 
reagents were obtained from Invitrogen. Other reagents not specified 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
2. Preparation of the P. morrowii extract  
The P. morrowii was collected at the coast of Jeju Island, Korea. 
The dried P. morrowii was initially rehydrated with 60% methanol in 
10 volumes to the dry weight of the seaweed at room temperature with 
vigorous stirring overnight. Upon removal of the solvent (denoted as 
the 60% extract), the wet seaweed was re-extracted with 7 volumes of 
100% methanol four times for 10 to 14 hr per each extraction at room 
temperature (denoted as the 100% extract). The 60% and the 100% 
extract were pooled and evaporated at 52°C using a rotary evaporator 
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until the volume reaches the one tenth of the original volume. The 
extract was re-extracted once with the same volume of ethyl acetate. 
After complete evaporation of ethyl acetate, the dried extract were 
weighed and solubilized with 100% methanol at a concentration of 50 
mg/ml and stored at -20°C, and used as the P. morrowii extract. The P. 
morrowii extract was further fractionated by hydrophobic interaction 
chromatography using octadecylsilyl (ODS) column (YMC Co. Ltd., 
Kyoto, Japan) with differential concentrations of methanol. The 
fractions were dried by evaporation, dissolved in 100% methanol, and 
stored at -20°C. For administration of the extract to mice and treatment 
of cells, each extract was dried completely to remove methanol and 
solubilized in DMSO just before use. 
 
3. Cell culture 
HepG2 (ATCC number HB-8065) cells were maintained in medium 
A (DMEM containing 100 units/ml penicillin and 100 µg/ml 
streptomycin sulfate) supplemented with 10% (v/v) fetal bovine serum 
(FBS) at 37°C under a humidified atmosphere of 5% CO2. For 
induction of SCD1, cells were set up on day 0 (2 × 105cells/well in 12 
well plate) in medium A supplemented with 10% FBS. On day 1, cells 
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were washed twice with PBS and changed to medium A supplemented 
with 10% DLPS in the presence or absence of the P. morrowii extract at 
indicated concentration. On day 2, cells were washed twice with PBS, 
harvested, and processed for immunoblot analyses.  
Preadipocyte 3T3-L1 cells were maintained in medium A DMEM 
containing 8 µg/ml biotin, and supplemented with 10% (v/v) heat-
inactivated calf serum at 37°C under a humidified atmosphere of 10% 
CO2. To induce differentiation of 3T3 cells, on post-confluent day 2, 
cells were changed to medium A supplemented with 10% FBS and 
MDI (0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, and 
1 μg/ml insulin), then maintained for 2 days. Cells were then changed to 
DMEM medium containing 10% FBS and 1 μg/ml insulin. Two days 
after final medium change, cells were processed for oil-red O staining 
or harvested for immunoblot analyses. 
 
4. Immunoblot analysis 
After treatment, cells were washed with PBS and lysed with 100 μl 
of lysis buffer containing 0.33 M NaCl, 1.1 M urea, 1% Nonidet P-40, 
25 mM HEPES (pH 7.6), and proteinase inhibitors (1 mM DTT, 10 
μg/ml leupeptin, 5 μg/ml pepstatin A, 1 mM PMSF and 2 μg/ml 
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aprotinin) by adding directly onto the plate. Cell lysates were harvested 
and further vortexed at room temperature for 5 min for the complete 
liberation of proteins. Lysate were cleared by centrifugation at 20,000 g 
for 10 min at 4°C, and the supernatants were collected as whole cell 
lysate. After quantitation of proteins, aliquots of proteins were 
subjected to 10 % SDS-PAGE and transferred onto nitrocellulose ECL 
membranes (GE Healthcare, Piscataway, NJ, U.S.A.) and immunoblot 
analyses were performed using the SuperSignal West Pico 
Chemiluminescent Substrate System (Pierce). The following antibodies 
were used in the current studies: anti-SCD1 and anti-GAPDH from Cell 
Signaling Technology, Inc. Horseradish peroxidase-conjugated 
secondary antibodies were obtained from Pierce. The polyclonal 
antibodies against human FASN and ACLY were kindly provided by 
Kyung-sup Kim (Department of Biochemistry and Molecular Biology, 
Yonsei University College of Medicine, Seoul). 
 
5. Microarray analysis and quantitative real-time PCR (RT-PCR) 
Total RNA was prepared from HepG2 cells or livers of mice using 
an RNeasy Mini kit (Qiagen, Valencia, CA, USA) or Trizol reagent 
(Invitrogen), respectively, according to the manufacturer’s instruction. 
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The total RNAs from livers of mice were subjected to a microarray 
analysis using Illumina MouseRef-8 v2 expression BeadChip (Illumina, 
Inc., San Diego, CA). The bioinylated cRNA were prepared from 0.55 
µg of total RNA using the Illumina TotalPrep RNA amplification Kit 
(Ambion, Austin, TX). Following fragmentation, 0.75 µg of cDNA 
were hybridized to the chip according to the protocols provide by the 
manufacturer. Array were scanned using the Illumina Bead Array 
Reader Confocal Scanner. The array data export processing and 
analysis were performed using Illumina GenomeStudio v.2011.1. 
For RT-PCR, removal of DNA from RNA was achieved by a DNA-
free kit (Ambion Brand, Life Technologies, Austin, TX) for RNA from 
tissues or with an RNase-Free DNase (Qiagen) for RNA from cells. 
cDNA was synthesized from 2 μg of DNase-treated total RNA using a 
High-Capacity cDNA Archive kit (Applied Biosystems Brand, Life 
Technologies, Foster City, CA, USA). Quantitative RT-PCR was 
performed using StepOne™ Real-Time PCR Systems (Applied 
Biosystems). All reactions were done in dulicate, and relative amounts 
of all mRNAs were calculated by the comparative cycle-time method.51 
GAPDH mRNA was used as the invariant control. The sequences of the 
specific primers for each gene are as follows:  
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Forward primer for Scd1: 5'-AGCGGTACTCACTGGCA-3'  
Reverse primer for Scd1: 5'-CCTACGACAAGAACATTCAATCC-3' 
Forward primer for Elovl1: 5'-ATCAGCTCGTGGTACAAGTTC-3' 
Reverse primer for Elovl1: 5'-CCTGATCCCTTTGAACCC-TTC-3' 
Forward primer for Elovl6: 5'-GTACAGCATG-TAAGCACCAGT-3' 
Reverse primer for Elovl6: 5'-CAAGCGAGCCAAGTTTGAAC-3' 
Forward primer for Fasn: 5'-GCTGCGGAAACTTCAGGAAAT-3' 
Reverse primer for Fasn: 5'-AGAGACGTGTCA-CTCCTGGACTT-3' 
Forward primer for Acly: 5'-GCCAGCGGGAGCACATC-3' 
Reverse primer for Acly: 5'-CTTTGCAGGTGCCAC-TTCATC-3' 
Forward primer for Srebp-1c: 5'-GCAGCCATGGATTGCACATT-3' 
Reverse primer for Srebp-1c: 5'-GGCCCGGGAAGTCACTGT-3' 
Forward primer for Gapdh: 5'-TGTGTCCGTCG-TGGATCTGA-3' 
Reverse primer for Gapdh: 5'-CCTGCTTCACCACCTTCTTGAT-3' 
Forward primer for GAPDH: 5'-GCCCCAGCGTCAAAGGT-3' 
Reverse primer for GAPDH: 5'-GGCATCCTGGGCTACACTGA-3' 
The primers for human SCD1 were purchased from Qiagen (Cat. No: 
QT00052381).  
 
 
  
16 
6. Cell cytotoxicity assay  
Cytotoxic effect of the P. morrowii extract on the viability of HepG2 
cells were determined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] assay using the CellTiter 96® Non-
Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA). 
HepG2 cells were grown in 96-well plates at a density of 0.5ⅹ104 cells 
per well in 0.25 ml of medium A supplemented with 10% FBS on day 0. 
On day 1, cells were washed twice with PBS and changed to medium A 
supplemented with 10% DLPS in the presence indicated concentration 
of the P. morrowii extract. Cell survival (% of control) was calculated 
as the absorbance at 470 nm of extract-treated cells relative to those of 
DMSO-treated control cells. 
 
7. Construction of the SCD1 promoter-reporter plasmids, transient 
transfection, and reporter assay  
The first base of the translated ATG in the human SCD1 genomic 
sequence was arbitrarily annotated as +1. The SCD1 promoter 
fragment35 spanning from -1407 to -1 was amplified by PCR from 
human genomic DNA using the following primers: 5'-
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ATGGTGTTTCTGGGCTCAAC-3' and 5'-ACCATCAAGCTTCTTG-
GCTCTCGGATGCC-3'. The amplified DNA product was digested 
with KpnI and HindIII and gel-purified using the Gel purification kit 
(Intron Biotechnology, Sungnam, Kyungkee-do, Korea). This digested 
fragment (-1295 to -1) was cloned into KpnI and HindIII sites of pGL3-
basic vector (Promega). Mutant clones for LXR response element 
(LXRE)52, the binding site for CCAAT/enhancer-binding proteins 
(C/EBPs)53 and sterol regulatory element (SRE)35 were generated from 
the wild-type SCD1 promoter construct using the QuickChange site-
directed mutagenesis kit (Agilent Technologies) and the following 
forward primers: LXRE mutant, 5'-
AGGAAATACCGGACACAATCACCCGTAACCAGCTCTAGCCTT
TAAA-3'; C/EBPs mutant, 5'-CGGATAAAAGGGGGCCTAGAAG-
ATACCGGACACGGTC-3'; SRE mutant, 5'-
GGCGGCAGAGGGAACCGCC-GCTTGCGCCGAGCCAAT-3'. 
Locations of mutated nucleotides are underlined. The sequences of 
reverse primers are complementary to those of forward primers. The 
integrity of construct sequences was confirmed by DNA sequencing. 
HepG2 cells were transiently cotransfected in suspension state with 
promoter-reporter constructs and pTK-renilla control vector (Promega) 
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using Lipofectamine 2000 (Invitrogen) according to the method 
described by Jeong et al.54 and luciferase activity was analyzed by the 
Dual-luciferase reporter assay system (Promega, Madison, WI, USA) 
according to the manufacturer’s instruction. Briefly, on day 0, HepG2 
cells were transfected with plasmids, and cells were changed to medium 
A supplemented with 10% DLPS in the presence or absence the P. 
morrowii extract on day 1. On day 2, cells were washed twice with PBS, 
harvested, and cell lysate were prepared with passive lysis buffer 
(Promega) according to the manufacturer’s instructions. The firefly 
luciferase activity driven by the SCD1 promoter was normalized by the 
renilla luciferase activity and the amounts of protein in the lysate. 
 
8. Animal experiments 
Eight- to 10-week old male C57BL/6J mice purchased from Japan 
SLC, Inc. (Shizuoka Prefecture, Japan) were maintained on 12-h 
dark/12-h light cycles and fed a standard chow diet (LabDiet, St. Louis, 
MO, USA) ad libitum and had free access to tap water. All mice were 
sacrificed at the end of the dark cycle. The diet supplemented with the P. 
morrowii extract was prepared by adding the extract at a concentration 
of 40 mg% (w/v) into the milled chow diet. The powered diets were 
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reformed into pellets with the minimum amounts of distilled water. The 
mock diet contained the DMSO only as a vehicle. After treatment, 
livers were collected and stored at -80°C until later use. All animal 
experiments were performed with the approval of the Institutional 
Animal Care and Research Advisory Committee at Yonsei University 
College of Medicine. 
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III. RESULTS 
1. The P. morrowii extract lowers the level of plasma TG 
To evaluate the effect of the P. morrowii extract in mice, 8 to 10-
week old male mice were fed a standard chow diet supplemented with 
40 mg% (w/w) of the extract ad libitum for 82 day. Assuming that a 
mouse eats 5 g of diet a day, the concentration at 40 mg% of the extract 
in the diet was postulated to supply a mouse in 25 g of body weight 
with the extract in the amount of 80 mg/kg of body weight per day. 
Table 1 lists several relevant metabolic parameters of mice fed a diet 
with the P. morrowii extract. The plasma concentration of TG in mice 
fed with the P. morrowii extract was decreased significantly by 49% (P 
< 0.01) compared to that in control mice fed a chow diet supplemented 
with DMSO, the vehicle for the extract solubilization. The reduction of 
TG in plasma by the P. morrowii extract was observed consistently in 3 
independent experiments. However, the other parameters remained 
unchanged by the P. morrowii extract. 
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Table 1. Metabolic parameters of mice fed with the P. morrowii 
extract 
Parameter DMSO P. morrowii 
No. & Sex 9 males 10 males 
Body weight (g) 33.5 ± 1.2 33.5 ± 0.6 
Liver weight (g) 1.63 ± 0.06 1.58 ± 0.34 
Liver wt./body wt. 4.88 ± 0.10 4.72 ± 0.04 
Plasma TG (mg/dl) 155 ± 10.4 79 ± 7.6* 
Plasma cholesterol (mg/dl) 97 ± 4.81 79 ± 3.9 
Male mice, 8-10 weeks of age, were fed a chow diet supplemented with 
40 mg% (w/w) of the P. morrowii extract ad libitum for 82 days. Each 
value represents the mean ± S.E. of 9 or 10 values. Asterisks denote the 
level of statistical significance (Student’s t test). *, P < 0.05. The 
similar results were observed in three independent experiments. 
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2. Expression of lipogenic genes in livers of mice was decreased by 
the P. morrowii extract 
To determine the effect of the P. morrowii extract on the genes 
related to TG metabolism, the microarray analysis was performed using 
total RNA was isolated from pooled livers of mice described in the 
Table 1. Microarray analysis identified 201 genes up-regulated more 
than 30% in livers of mice fed a diet supplemented with the P. 
morrowii extract, and 288 genes down-regulated more than 30% by the 
P. morrowii extract. Among these affected genes, 12 lipogenic genes 
were focused for further evaluation in this study (Table 2). Table 3 
shows the changes in transcripts of genes that play an important role in 
triacylglycerol metabolism.  
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Table 2. Number of genes whose transcripts changed by more than 
30% in livers of mice by the P. morrowii extract analyzed 
by cDNA microarray 
Gene cluster Up-regulated Down-regulated 
Apoptosis 1 1 
Amino acid metabolism 2 5 
Carbohydrate metabolism 7 3 
Cell cycle 1 6 
Lipid, fatty acid metabolism 12 27 
Each value represents the number of genes of which mRNAs were up- 
or down-regulated in livers of mice fed a chow diet supplemented with 
the P. morrowii extract as described in Table 1. 
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Table 3. Relative levels of gene transcripts which decreased 
significantly in livers of mice by the P. morrowii extract 
analyzed by cDNA microarray  
Gene Relative expression 
Srebp-1 0.74 
Fasn 0.70 
Elovl1 0.66 
Acly 0.61 
Scd1 0.57 
Elovl6 0.5 
Each value represents the relative level of gene transcripts in livers of 
mice fed the P. morrowii extract compared to that in livers of control 
mice, which is arbitrarily defined as 1. Srebp-1, sterol regulatory 
element-binding protein-1; Fasn, fatty acid synthase; Elovl1, ELOVL 
family member 1, elongation of long chain fatty acids; Acly, ATP 
citrate lyase; Scd1, stearoyl-CoA desaturase-1; Elovl6, ELOVL family 
member 6, elongation of long chain fatty acids. 
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Changes in the expression of selected genes were further verified by 
RT-PCR using the total RNA isolated from pooled livers of mice used 
in the experiment for the Table 1 (Fig. 1). Amounts of Fasn, Scd1, and 
Elovl6 mRNAs were decreased by the P. morrowii extract to the levels 
comparable to those analyzed by microarray, while amounts of Srebp-
1c and Acly mRNAs has changed in a minimal range. RT-PCR 
quantification showed no significant change in the amount of Elovl1 
mRNA by the extract. Immunoblot analysis showed that the amount of 
Scd1 protein was decreased most significantly in livers of mice fed a 
diet supplemented with the P. morrowii extract compared to that in 
control mice, while changes in amounts of Fasn and Acly proteins by 
the extract were relatively small (Fig. 2). These results suggest that 
expression of SCD1 is a potential target for reduction of the plasma 
concentration of triacylglycerol by the P. morrowii extract. 
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Figure 1. Effect of the P. morrowii extract on amounts of mRNAs 
for lipogenic genes in livers of mice analyzed by RT-PCR 
Total RNAs from pooled livers of mice described in Table 1 were 
subjected to RT-PCR as described under “Materials and Methods”. 
Each value represents the amount of mRNA in livers of mice fed the P. 
morrowii extract (P. morrowii) relative to that in livers of control mice 
(DMSO), which is arbitrarily defined as 1. The amount of mRNA was 
normalized by that of Gapdh mRNA. Values were measured in 
duplicate reactions. Similar results were obtained in two independent 
experiments.  
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Figure 2. Effects of the P. morrowii extract on the expression of 
lipogenic enzymes in livers of mice analyzed by 
immunoblot 
Lysates were prepared from pooled livers of two or three mice of the 
control group (DMSO) or from individual livers in the extract-fed group 
(P. morrowii). Mice used in this experiment are described in Table 1. 
The aliquotes of protein were subjected to SDS-PAGE and immunoblot 
analysis as described under “Materials and Methods”. Fasn, fatty acid 
synthase; Acly, ATP citrate lyase; Scd1, stearoyl-CoA desaturase 1; 
Gapdh, glyceraldehyde dehydrogenase. 
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3. Determination of the highest concentration of the P. morrowii 
extract for treatment in HepG2 cells 
For determination of the highest concentration of the P. morrowii 
extract applicable to an experiment in vitro, cell toxicity was evaluated 
by the MTT assay. The treatment of HepG2 cells with the extract at 
concentrations of up to 100 μg/ml showed a minimal cytotoxic effect 
both for 18hr (86% viability compared to vehicle treated cells, Fig. 3A) 
and for 3 days (82% viability compared to vehicle treated cells, Fig. 3B). 
The viability of HepG2 cells were dramatically decreased by treatment 
with the extract at a concentration 1 mg/ml for 18 hr (34% viability 
compared to vehicle treated cells). These results suggest that IC50 (half 
maximal inhibitory concentration) of the P. morrowii extract is between 
300 μg/ml and 1 mg/ml when treated for 18 hr. According to this 
cytotoxicity evaluation, the concentration of the P. morrowii extract at 
100 μg/ml or below was used in following studies in vitro.  
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Figure 3. Cell viability assay of the P. morrowii extract in HepG2 
cells 
HepG2 cells were treated with indicated concentrations of P. morrowii 
extracts for 18 hr (A) or 3 days (B) in medium A supplemented with 10% 
FBS, and cell viability was determined by using MTT assay as 
described under “Materials and Methods”. For 3-day treatment, fresh 
medium with the extract was changed at 48 hr after initial treatment. 
Values represent the cell viability relative to that in vehicle-treated cells 
(DMSO) which is arbitrarily defined as 1. Each value represents mean ± 
SD from triplicate reactions.   
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4. Expression of SCD1 is decreased by the P. morrowii extract in 
HepG2 cells 
To determine whether SCD1 expression is decreased by the P. 
morrowii extract in vitro, HepG2 cells were setup in medium A 
supplemented with 10% FBS for 24h, then changed to medium A 
supplemented with 10% DLPS in the presence of indicated 
concentrations of the P. morrowii extract for 18 hr. The expression of 
SCD1 was evaluated by immunoblot analysis and RT-PCR. The P. 
morrowii extract decreased the amount of the SCD1 protein (Fig. 4A) 
and mRNA (Fig. 4B) in a dose-dependent manner.  
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Figure 4. Regulation of SCD1 by the P. morrowii extract in HepG2 
cells  
(A) HepG2 cells were treated with the indicated concentration of the P. 
morrowii extract for 18 hr, and the whole cell lysates were subjected to 
immunoblot analysis for stearoyl-CoA desaturase-1 (SCD1). GAPDH 
protein was used as a loading control. (B) Total RNAs from the cells 
were prepared and subjected to quantitative RT-PCR as described under 
“Materials and Methods”. The quantity of mRNA was normalized to 
that of GAPDH mRNA. Each value represents the relative amount of 
SCD1 mRNA compared to that in vehicle-treated cells (the 
concentration of 0) in triplicate reactions. Similar results were obtained 
in three independent experiments.  
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5. Expression of SCD1 is decreased by the P. morrowii extract in 
3T3-L1 preadipocytes 
To determine whether the P. morrowii extract has the same effect in 
cells with more active fat metabolism than HepG2 cells, the expression 
of Scd1 in 3T3-L1 cells, a well-characterized model of adipogenesis55, 
was also evaluated. 3T3-L1 cells were treated with the P. morrowii 
extract at indicated concentrations on the day of induction of 
differentiation by MDI (day 0; Fig. 5, D0), and the expression of Scd1 
was determined at different time points after induction of differentiation. 
Fig. 5A shows that preadipocytes 3T3-L1 cells on day 0 barely express 
Scd1 protein in an undetectable level by immunoblot analysis with the 
antibody used in this study. On day 2, the expression of Scd1 protein 
and mRNA (Fig. 5B) in 3T3-L1 cells increased sharply, and continued 
to increase by day 4. The extract significantly blocked this induction of 
Scd1 in a dose-dependent manner. To evaluate the change in Scd1 
mRNA, a quantitative RT-PCR was carried out using the total RNA 
isolated from 3T3-L1 cells and analyzed by RT-PCR. Treatment of 
3T3-L1 cells with the P. morrowii extract decreased the expression of 
Scd1 mRNA significantly (Fig. 5B). On day 4, the mRNA level of Scd1 
was decreased by the extract approximately to 48% compared to control. 
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These data suggest that the P. morrowii extract effectively blocks 
expression of Scd1 in the course of differentiation of 3T3-L1 
preadipocytes to adipocytes.  
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Figure 5. Effects of the P. morrowii extract on Scd1 expression in 
the process of adipocyte differentiation 
Preadipocyte 3T3-L1 cells were induced for differentiation as described 
under “Materials and Methods”, and effects of the P. morrowii extract 
on the expression of Scd1 in the process of 3T3-L1 differentiation were 
determined by immunoblot analysis (A) and by quantitative RT-PCR 
(B). D0 denotes the post-confluent cells before induction of 
differentiation by MDI. In RT-PCR experiment (B), the extract was 
treated to cells at a concentration of 30 µg/ml (P. morrowii). Each value 
in (B) represents the relative amount of mRNA compared to that in 
vehicle-treated cells (DMSO) on day 0 in duplicate reactions. Similar 
results were obtained in three independent experiments.  
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6. Regulation of transcriptional activity of the human SCD1 
promoter by the P. morrowii extract 
To determine whether decrease in the SCD1 mRNA by the P. 
morrowii extract is caused by transcriptional regulation of the SCD1 
promoter, HepG2 cells were transiently transfected with SCD1 
promoter-reporter constructs and luciferase reporter assay was 
performed. The transcriptional activity of the SCD1 promoter region (-
1295 to -1) was decreased by the P. morrowii extract in a dose-
dependent manner (Fig. 6). This result suggests that the expression of 
SCD1 is down-regulated by the P. morrowii extract at a transcriptional 
level.  
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Figure 6. Down-regulation of the SCD1 promoter activity by the P. 
morrowii extract in HepG2 cells 
HepG2 cells were transiently cotransfected with the SCD1 promoter-
reporter constructs and pRL-RSV renilla vector, and luciferase activity 
was analyzed as described under “Materials and Methods”. The firefly 
luciferase activity driven by the promoter was normalized to the renilla 
luciferase activity and the amounts of protein in the lysate. The relative 
luciferase activity denotes the promoter activity in cells treated with the 
extract at the indicated concentration of the extract relative to that in 
cells treated with DMSO (concentration at 0). Each value represents the 
mean ± SD of three independent experiments (each in duplicate 
reactions).  
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7. Regulation of transcription factors by the P. morrowii extract in 
the SCD1 promoter  
To determine the functionally important DNA elements that mediate 
the transcriptional regulation of the SCD1 promoter by the P. morrowii 
extract, mutant clones for consensus sequences that are reported to be 
implicated in lipid metabolism were generated and the reporter assay 
was carried out (Fig. 7). Sequence analysis revealed that human SCD1 
promoter region spanning from -1295 to -1 contains several potential 
transcription factor-binding elements as follows: LXRE52, the binding 
site for C/EBP35, and SRE35. Quadrilaterals are locations of mutated 
nucleotides (Fig 7A). The P. morrowii extract reduced the 
transcriptional activity of the wild-type SCD1 promoter (Fig 7B) as 
shown above in Fig. 6. Introduction of mutations in LXRE and SRE in 
the SCD1 promoter resulted in reduced basal transcriptional activity 
compared to that of the wild-type construct, while mutations in C/EBP 
resulted in slight increase in basal transcriptional activity. Although 
these consensus elements are expected to play an important role for 
SCD1 transcription, any mutations had no effect on the action of the P. 
morrowii extract to reduce SCD1 transcription by 44% (SRE mutant) to 
67% (C/EBP mutant). These results suggest that down-regulation of the 
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SCD1 transcription by the P. morrowii extract is achieved by the other 
mechanism than involving transcription factors reported previously, and 
that future elucidation of a new pathway mediating down-regulation of 
the SCD1 expression by the extract is required.  
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Figure 7. Effects of mutations in transcription factor-binding sites 
on SCD1 transcription by the P. morrowii extract in 
HepG2 cells 
(A) These nucleotides are the digested fragment (-1295 to -1) for the 
wild-type SCD1 promoter construct. Mutant clones were generated 
from the wild-type SCD1 promoter construct using the Quick Change 
site-directed mutagenesis kit as described under “Materials and 
Methods”. (B) HepG2 cells were transfected with the wild-type or 
mutant constructs and luciferase-reporter assay was carried out after 
treatment of the P. morrowii extract at a concentration of 100 µg/ml. 
Each value represents the relative luciferase activity in cells compared 
to that in vehicle-treated cells which were transfected with the wild-type 
construct. (C) Values in panel A were recalculated to compare the effect 
of the extract for each mutant construct. Each value represents the 
relative luciferase activity in cells treated with the extract compared to 
that in cells transfected with the same construct and treated with vehicle 
(DMSO). Error bars denote the range for the two duplicate values. The 
similar results were obtained in two independent experiments. 
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Ⅳ. DISCUSSION 
The reduction of the plasma TG level is an important management to 
reduce the incidence of CVDs particularly in patients with obesity and 
diabetes1,2,6. Although the proper management of hyperglyceridemia is 
required for prevention of obesity, metabolic syndrome, and coronary 
heart diseases, specific and effective medicines for hyperglyceridemia 
are not fully available. This unavailability has led global pharmaceutical 
companies continue to search and develop efficient drugs for this 
purpose. 
Among several strategies of lowering the plasma TG concentration, 
strong support has been eluted from many researches for the inhibition 
of the expression and activity of SCD, the rate-limiting enzyme of de 
novo monounsaturated fatty acid synthesis, to be a potential therapeutic 
target in the prevention of metabolic diseases. The monounsaturated 
fatty acids synthesized by SCD1 are used as major substrates for TG 
and cholesteryl ester synthesis. Many studies have reported the possible 
link of SCD1 with treatment or prevention of obesity and dyslipidemic 
disorders21. For example, mice with disruption in the Scd1 gene showed 
increased insulin sensitivity and energy expenditure, reduced body 
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adiposity, and resistance to diet-induced obesity39. In addition, the 
expression and activity of Scd1 was specifically repressed by leptin 
leading to lean and hypermetabolic condition in leptin-deficient ob/ob 
mice 56. Most importantly, a disruption of the Scd1 gene in mice 
showed decreased body adiposity, increased energy expenditure, 
increased sensitivity, and resistance to diet-induced obesity39. 
In this study, the effect of the P. morrowii extract on the regulation 
of the expression of SCD1 was elucidated for development of 
therapeutics to lower the plasma concentration of TG. P. morrowii is a 
red algae distributed widely on the coast of Korea, and the importance 
of seaweeds has been extensively reported as a therapeutic resource57, 
however, only a few studies on P. morrowii has been reported inasmuch 
as therapeutic application is concerned. It has been reported that P. 
morrowii protects human keratinocytes from ultraviolet B radiation 
through the enhancement of antioxidant systems58. The other example is 
3-bromo-4,5-dihydroxylbenzyl methyl ether and 3-bromo-4,5-
dihydroxylbenzaldehyde isolated from P. morrowii to exhibit antiviral 
activity59. 
This study demonstrated that the extract of P. morrowii efficiently 
reduced the expression of lipogenic genes including Fasn, Scd1, Acly, 
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Srebp-1, Elovl1, and Elovl6 in wild-type C57BL6/J mice. Although not 
all genes were evaluated for their protein expression, it is supposed that 
Scd1 is one of important mediators to lower the plasma TG 
concentration. The down-regulation of SCD1 in vivo and in vitro was 
accompanied with decreased in its mRNA, and reduced transcriptional 
activity of the SCD1 promoter in HepG2 cells. 
For elucidation of transcriptional repression of the SCD1 promoter by 
P. morrowii, mutational analysis of cis-elements on the promoter was 
carried out. SREBP-1 is a key transcription factor to govern the whole 
pathway of de novo synthesis of fatty acids and TG. The SRE, the 
binding site for SREBPs is present in the SCD1 promoter and is 
important to the sterol-dependent transcription of the SCD1 promoter60. 
C/EBP is one of the major components in transcriptional control of 
SCD1 of adipogenesis and insulin sensitivity42 61. SCD1 deficiency can 
protect against hypertriglyceridemia induced by LXR activation11. 
Unfortunately, the mutations of these conserved cis-elements had no 
effect on the transcriptional activity of the SCD1 promoter by P. 
morrowii. This suggests that the other region or elements participate in 
regulation of transcription of SCD1 by P. morrowii. As a result, the 
precise mechanism that mediates repression of transcriptional activity 
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of the SCD1 promoter by P. morrowii was not provided in this study 
and requires to be further elucidated.  
In conclusion, this study provides strong support that the P. morrowii 
extract have potential to treat hyperglyceridemia and obesity by down-
regulation of SCD1. 
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V. CONCLUSION 
Elevated SCD1 activity has been implicated in a wide range of 
disorders including diabetes, atherosclerosis, and obesity. Therefore, 
modulation of SCD1 expression is one of the target to control 
hyperglyceridemia and obesity. This study indicates that expression of 
SCD1 protein and mRNA was efficiently repressed by P. morrowii, a 
red algae available in the coast of Korean, in vivo and in vitro. In vivo 
study showed decrease in the level of plasma TG by the P. morrowii. 
Although cis-elements that mediate the transcriptional repression of the 
SCD1 promoter by P. morrowii have not fully elucidated, it is 
suggested that the inhibition of SCD1 expression by P. morrowii is a 
potential therapeutic modality to treat hyperglyceridemia. 
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ABSTRACT (IN KOREAN) 
 
모로우붉은실 추출물에 의한 SCD1 발현 조절 기전 규명 
 
 
<지도교수 박 상 욱> 
 
연세대학교 대학원 의과학과 
 
이 나 래 
 
SCD1 (Stearoyl-Coenzyme A desaturase 1)은 포화지방산으로부터 
단일불포화지방산을 합성하는 효소로서 중성지방 (triglyceride, 
TG) 합성을 조절하는 주요 인자이다. SCD1은 기질인 stearoyl-
CoA의 9번째 탄소에 이중결합을 형성하여 oleoyl-CoA를 
합성한다. 혈중 중성지방의 증가는 고지혈증을 유발하고, 
고콜레스테롤혈증과 함께 심혈 관계 질환 발병률을 
증가시키며 인슐린 저항성을 유발시킨다. 고지혈증을 치료하는 
  
58 
여러 가지 방법이 임상적으로 사용되고 있으나 아직까지 
중성지방에 특이적이며 효과적으로 중성지방 농도를 
감소시키는 약물은 성공적이지 못하다. 최근 비만과 
이상지질혈증의 치료 표적으로서 SCD1에 대한 연구가 활발히 
진행되고 있다. 특히 Scd1이 결핍된 마우스는 비만 및 당뇨병 
발생이 정상 마우스에 비하여 감소됨이 보고되었다. 그래서 
이러한 근거로 본 연구에서는 고지혈증의 치료 약물을 개발 
하고자 해조류의 일종인 모로우붉은실 추출물이 SCD1 발현을 
억제함으로써 혈중 중성지방 농도를 감소시키는 효과가 
있음을 확인하였다. 이러한 작용은 마우스 및 HepG2 세포에서 
SCD1 단백질 및 mRNA의 감소를 통하여 이루어짐을 밝혔으며, 
SCD1 프로모터의 전사 활성이 모로우붉은실에 의하여 
감소됨을 밝혔다. SCD1 프로모터의 전사 억제 기전을 밝히고자 
LXRE, C/EBP 및 SRE 부위의 돌연 변이 유도 실험을 
진행하였으나 모로우붉은실의 전사 억제 작용은 큰 영향을 
받지 않았다. 따라서 보다 구체적인 SCD1 발현 조절 기전을 
향후 연구해서 밝힐 필요가 있다. 결론적으로 본 연구는 
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모로우붉은실이 SCD1 발현을 조절하여 고지혈증과 비만을 
치료 혹은 예방할 수 있는 새로운 약물로서의 개발 가능성을 
제시하였다. 
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